about
sameAs
Assisted reproductive technologies for male subfertilityGonadotrophins for ovulation induction in women with polycystic ovarian syndromeCulture media for human pre-implantation embryos in assisted reproductive technology cyclesRecombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndromeGonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technologyLife-style modification, non-pharmacological and pharmacological strategies for obese subfertile womenFresh versus frozen embryo transfers for assisted reproductionTamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproductionLow oxygen concentrations for embryo culture in assisted reproductive technologiesTamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproductionGonadotrophins for ovulation induction in women with polycystic ovarian syndromeHuman menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cyclesMetformin co-administration during follicle stimulating hormone ovulation induction with timed intercourse or intra-uterine insemination for subfertility associated with polycystic ovary syndromeGonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cyclesLow oxygen concentrations for embryo culture in assisted reproductive technologiesGonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cyclesRecombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cyclesLife-style modification, non-pharmacological and pharmacological strategies for obese subfertile womenCulture media for human preimplantation embryos in assisted reproductive technology cyclesGonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cyclesPreimplantation genetic screening for abnormal number of chromosomes (aneuploidies) in in vitro fertilisation or intracytoplasmic sperm injectionRecombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cyclesRecombinant versus urinary derived gonadotrophins for ovarian stimulation in in vitro fertilisation and intra-cytoplasmic sperm injection cyclesPulsatile gonadotrophin releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndromeHuman menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cyclesLow oxygen concentrations for embryo culture in assisted reproductive technologiesPrediction models in in vitro fertilization; where are we? A mini reviewCan dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysisTreatment strategies for women with WHO group II anovulation: systematic review and network meta-analysisUrinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis.The influence of the number of follicles on pregnancy rates in intrauterine insemination with ovarian stimulation: a meta-analysis.Individual patient data meta-analysis of diagnostic and prognostic studies in obstetrics, gynaecology and reproductive medicineThe INeS study: prevention of multiple pregnancies: a randomised controlled trial comparing IUI COH versus IVF e SET versus MNC IVF in couples with unexplained or mild male subfertility.Endometrial scratching in women with implantation failure after a first IVF/ICSI cycle; does it lead to a higher live birth rate? The SCRaTCH study: a randomized controlled trial (NTR 5342).Urofollitropin and ovulation induction.Predictive factors in in vitro fertilization (IVF): a systematic review and meta-analysis.Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis.Significance of (sub)clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: a systematic review.Prevention of multiple pregnancies in couples with unexplained or mild male subfertility: randomised controlled trial of in vitro fertilisation with single embryo transfer or in vitro fertilisation in modified natural cycle compared with intrauterinThe M-OVIN study: does switching treatment to FSH and / or IUI lead to higher pregnancy rates in a subset of women with world health organization type II anovulation not conceiving after six ovulatory cycles with clomiphene citrate - a randomised co
P50
Q24186103-6DAB52F1-7316-4DC3-9B38-CE5E8BB152D1Q24187261-F6F3FB44-D08E-49AE-A7A6-5E1FDF3006D4Q24187717-BDAD96A5-EB40-41CE-AA0E-5E7A54D7EECEQ24188049-172C8779-55F5-4052-981C-2C1C90AE32FFQ24193015-255CACBC-D84F-4516-9466-447A12CB2637Q24194950-169027DA-8C6A-49FE-83D4-20520BD8F1A0Q24195066-AA079C70-0BBB-4F35-A351-44D4E23B461BQ24197765-FE003CEF-29BA-41BF-AF1F-B645AEE25338Q24202167-3712E71D-B9A0-4AD0-B433-FEEDEDC353F6Q24202513-2F7E2865-DC54-4009-964B-D7CC55858D77Q24202664-A236DB52-2EC0-4657-A617-0A296BE33DBDQ24234251-9977A14C-7F4D-4053-99A3-586E8CDA7FACQ24234748-7232D8EE-6C03-4783-8705-E2B4DA94291AQ24234765-BECF304F-8D47-4F00-A290-8914AFB6D4DCQ24235420-C11F4D4A-B23E-4A2C-A52B-72AA30404EEDQ24236630-2D029816-7020-4EA9-89AC-21F2B9735379Q24236740-2B610B34-4E6F-4DC3-B7CC-95ABDB643DE1Q24240517-B23D4AEB-742F-4853-9098-4C7A6A23F2A5Q24240899-E0CC9227-A663-48B3-A35C-5E94F99E0A45Q24241061-B0AE7928-6A86-4645-8253-276C5C54EEECQ24244735-CF94254B-CCE6-4CE4-89A1-4A431FDEE995Q24245184-DB6F9869-4E78-4010-9D89-00628179F3ACQ24246882-A15E7599-CFD7-4788-B3A1-461A2B611893Q24248029-6E65F6D4-E7B3-4964-A6B0-277F0DD24B7BQ24250231-5E64445C-5703-4BA0-8F16-D40B1261F0C2Q27026076-52E9726D-FA80-42D5-9B31-9E5F4D104AF9Q28083181-3F09A2E5-4DE6-4DAE-BFAC-6FDB78AF3D80Q28278251-8F6743DF-389C-43CB-9286-CF0C4992356DQ30847984-E2F1FB7F-52BB-4AA0-B821-43F8238308D8Q33308480-3B4E3CF0-CC6A-4C3A-8BCC-3A754A7898C8Q33358614-B9F83853-76B5-4842-A038-BF2EEFB06039Q33423248-AD742A77-723B-49BE-B896-4ECBA1BE0E4FQ33519719-52950454-E47D-45B3-ABA0-EAFCEBAF857DQ33923002-BE9D5436-ED97-4732-BA74-CBF6B492B67BQ33987216-CE8BA248-2EAC-4A3C-BAC5-ACADE02827E4Q34122926-952EE7C3-7D6D-405D-8B73-370BAB1118EEQ34141154-BCE0D2F6-F957-4BEB-8779-A303DEDE3ADFQ34188244-4D6BF0A5-1CE7-42C9-B9CF-D56EB7D3C4FBQ34885972-08873A70-4A50-4EC5-8B2D-2AD78A9DE37EQ35026310-A0073C52-755B-4D74-9C08-53A2CBA069E9
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Madelon van Wely
@ast
Madelon van Wely
@en
Madelon van Wely
@es
Madelon van Wely
@nl
Madelon van Wely
@sl
type
label
Madelon van Wely
@ast
Madelon van Wely
@en
Madelon van Wely
@es
Madelon van Wely
@nl
Madelon van Wely
@sl
prefLabel
Madelon van Wely
@ast
Madelon van Wely
@en
Madelon van Wely
@es
Madelon van Wely
@nl
Madelon van Wely
@sl
P106
P108
P1153
6701456330
P21
P31
P496
0000-0001-8263-213X
P569
2000-01-01T00:00:00Z